Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study - Iguchi, Taro; Tamada, Satoshi; Kato, Minoru; Yasuda, Sayaka; Machida, Yuichi; Ohmachi, Tetsuji; Ishii, Keiichi; Iwata, Hiroyuki; Yamamoto, Shinji; Kanamaru, Tomohiro; Morimoto, Kazuya; Hase, Taro; et al. (International journal of clinical oncology, 2020)
Keywords: Aged; Aged, 80 and over; Androgen Antagonists - therapeutic use; Androgens; Anilides - administration & dosage; Antigens; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; Castration; Flutamide; Flutamide - administration & dosage; Humans; Kallikreins - blood; Male; Medicine; Medicine & Public Health; Middle Aged; Nitriles - administration & dosage; Oncology; Original Article; Patients; Phenylthiohydantoin - administration & dosage; Phenylthiohydantoin - analogs & derivatives; Progression-Free Survival; Proportional Hazards Models; Prostate cancer; Prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Surgical Oncology; Survival; Tosyl Compounds - administration & dosage; Treatment Outcome; Castration-resistant prostate cancer; Flutamide; Enzalutamide; Randomized controlled trial